CAS: 868662-36-6; (6-(Trifluoromethyl)Pyridin-3-yl)Boronic Acid

相似化合物

1218790-39-6 947533-39-3 1245906-75-5

上下游产品

Triisopropyl borate water 5-bromo-2(trifluoromethyl)pyridine 2,5-dibromopyridine (S)-1-((4-fluorophenyl)sulfonyl)-N-((6-(6-(trifluoromethyl)pyridin-3-yl)pyrimidin-4-yl)methyl)pyrrolidine-2-carboxamide

5-溴-2-三氟甲基吡啶置于正丁基锂,硼酸三异丙酯,水体系中,用 四氢呋喃,正己烷 作为反应溶剂,化学反应 3.0H,以95%的收率获得产物2-三氟甲基-5-吡啶硼酸
参考文献:三氟甲基取代的吡啶基和吡唑基硼酸和酯:合成和suzuki-Miyaura交叉偶联反应†
标题:三氟甲基取代的吡啶基和吡唑基硼酸和酯:合成和suzuki-Miyaura交叉偶联反应†
摘要:三氟甲基取代的吡啶基硼酸和吡唑基硼酸酯的合成通过锂化-硼化方法进行了描述(方案1,3和4).提出了他们的钯催化的杂芳基卤化物交叉偶联的研究.由此获得cf 3取代的芳基/杂芳基-吡啶(51-98%的收率).类似的交叉偶联产生了杂芳基-3-(三氟甲基)吡唑(60-85%的收率).吡唑基硼酸酯的均偶联通过加入甲酸钾,尽管观测到竞争的原去硼.所选4位的卤化吡唑偶联产物允许进一步的交叉偶联以产生四取代的吡唑基衍生物(方案5).报道了选定的吡啶基硼酸,吡唑基硼酸酯和衍生的三氟甲基取代的杂联芳基系统的x射线晶体结构.这些多环cf 3取代的体系作为药物发现和材料化学的基础材料而受到关注.
DOI:10.1039/b901024F

专利信息

专利号:US-2024309003-A1
优先权日:2021-05-04
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN; PANDYA BHAUMIK; KAPLAN ALAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-2025304580-A1
优先权日:2021-11-09
标 题:Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; PANDYA BHAUMIK; KAPLAN ALAN P; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?).This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-9493461-B2
优先权日:2013-02-07
标 题 :Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C
发明人：DAI XING; LIU HONG; PALANI ANANDAN; HE SHUWEN; LAI ZHONG; NARGUND RAVI; MARCANTONIO KAREN; XIAO DONG; BROCKUNIER LINDA L; ZORN NICOLAS; DANG QUN; PENG XUANJIA; LI PENG
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

专利号:US-12319691-B2
优先权日:2020-05-04
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：CZABANIUK LARA C; HOPPER TIMOTHY; HOUZE JONATHAN B; RESCOURIO GWENAELLA; SANTORA VINCENT; WANG HAOXUAN; WHITE RYAN D; WONG ALICE R; WU YONGWEI
权利人:AMGEN INC; VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?).This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-12428425-B2
优先权日:2020-05-04
标 题:Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：CZABANIUK LARA C; HOPPER TIMOTHY; HOUZE JONATHAN B; PANTELEEV JANE; RESCOURIO GWENAELLA; SANTORA VINCENT; WANG HAOXUAN; WHITE RYAN D; WONG ALICE R; WU YONGWEI; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN
权利人:AMGEN INC; VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?).This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-9243002-B2
优先权日:2013-02-07
标题 :Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C
发明人：DAI XING; LIU HONG; PALANI ANANDAN; HE SHUWEN; BROCKUNIER LINDA L; NARGUND RAVI; MARCANTONIO KAREN; ZORN NICOLAS; XIAO DONG; PENG XUANJIA; LI PENG; GUO TAO
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.